Opigolix

Last updated
Opigolix
Opigolix.svg
Clinical data
Other namesASP-1707
Routes of
administration 		By mouth
Drug class GnRH modulator; GnRH antagonist; Antigonadotropin
Identifiers
  • (2R)-N'-[5-[3-(2,5-difluorophenyl)-2-(1,3-dihydrobenzimidazol-2-ylidene)-3-oxopropanoyl]-2-fluorophenyl]sulfonyl-2-hydroxypropanimidamide
CAS Number
PubChem CID
UNII
KEGG
Chemical and physical data
Formula C25H19F3N4O5S
Molar mass 544.51 g·mol−1
3D model (JSmol)
  • C[C@@H](O)/C(N)=N/S(=O)(=O)c1cc(C(=O)C(C(=O)c2cc(F)ccc2F)=C2Nc3ccccc3N2)ccc1F
  • InChI=1S/C25H19F3N4O5S/c1-12(33)24(29)32-38(36,37)20-10-13(6-8-17(20)28)22(34)21(23(35)15-11-14(26)7-9-16(15)27)25-30-18-4-2-3-5-19(18)31-25/h2-12,30-31,33H,1H3,(H2,29,32)/t12-/m1/s1
  • Key:CWNLBPBIFALUQD-GFCCVEGCSA-N

Opigolix (INN Tooltip International Nonproprietary Name, USAN Tooltip United States Adopted Name; developmental code name ASP-1707) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone antagonist (GnRH antagonist) which was under development by Astellas Pharma for the treatment of endometriosis and rheumatoid arthritis. [1] [2] It was also under investigation for the treatment of prostate cancer. [1] It reached phase II clinical trials for both endometriosis and rheumatoid arthritis prior to the discontinuation of its development in April 2018. [1]

Contents

See also

References

  1. 1 2 3 "Opigolix - Astellas Pharma - AdisInsight".
  2. ↑ Ezzati M, Carr BR (2015). "Elagolix, a novel, orally bioavailable GnRH antagonist under investigation for the treatment of endometriosis-related pain". Women's Health. 11 (1): 19–28. doi: 10.2217/whe.14.68 . PMID   25581052.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.